Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:41:08 01/09/2026			Varia. 5j.	Varia. 1 janv.
39,46 ^USD	-0,42%		-2,32%	+45,91%

06/08	Flash résultats (CLDX) : Celldex Therapeutics, Inc. publie un chiffre d'affaires de 0,0 million de dollars au deuxième trimestre	MT
06/08	Celldex Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

06/08	Celldex: Q2 Earnings Snapshot
06/08	Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M
06/08	Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Celldex Reports Second Quarter Financial Results and Provides Corporate Update
22/07	Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says
21/07	Celldex Therapeutics Discontinues Phase 2 Study of Barzolvolimab in Prurigo Nodularis After Missing Primary Endpoint
21/07	Celldex to stop skin disease study after trial setback
21/07	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
15/07	Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027
15/07	Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027
15/07	Celldex Therapeutics CFO Plans to Retire in 2027
15/07	Celldex Announces Planned Transition of Chief Financial Officer
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 2500 Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 2000 Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 3000E Growth Benchmark
29/06	Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 3000 Growth Benchmark
14/06	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU
14/06	Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06	Celldex Therapeutics, Inc. Presents Positive First-In-Human Results From Phase 1 Study Of Novel Bispecific CDX-622 At The European Academy Of Allergy And Clinical Immunology Annual Meeting
10/06	Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
08/05	Celldex Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Celldex: Q1 Earnings Snapshot
07/05	Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K